Baird Financial Group, Inc. Nurix Therapeutics, Inc. Transaction History
Baird Financial Group, Inc.
- $54.4 Billion
- Q2 2025
A detailed history of Baird Financial Group, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 110,000 shares of NRIX stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110,000Holding current value
$1.39 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
175Shares Held
79.5MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$86.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$76.5 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$56.4 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$49.8 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $595M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...